Literature DB >> 23824297

Can long-term bisphosphonate use causes low-energy fractures? A case report.

T Dandinoğlu1, S Akarsu, M Karadeniz, L Tekin, S Arıbal, M Z Kıralp.   

Abstract

Bisphosphonates are inorganic pyrophosphate analog which accumulate on the bone surface, cause osteoclast apoptosis, and inhibit bone resorption. The nitrogen-containing bisphosphonates continue to be the drug of choice for the treatment of osteoporosis in both men and women. Although histomorphometric studies including bone biopsies have not shown any evidence of microcracks, recent studies have revealed that potent bisphosphonates are responsible for the oversuppression of bone turnover leading to microdamages, reduced bone strength, and increased fracture risk. There are individual cases reporting atypical femoral fractures and severely suppressed bone turnover along with long-term (≥ 5 years) use of biphosphonates. In this study, we report on a 74-year-old woman with a history of continuous alendronate use for nearly 16 years who presented to the emergency department with right proximal humerus and left femur fracture.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23824297     DOI: 10.1007/s00198-013-2428-0

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  16 in total

1.  Alendronate-associated ulnar and tibial fractures: a case report.

Authors:  Zhi Hao Tang; Veerasingam Prem Kumar
Journal:  J Orthop Surg (Hong Kong)       Date:  2011-12       Impact factor: 1.118

2.  Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution.

Authors:  S-K Goh; K Y Yang; J S B Koh; M K Wong; S Y Chua; D T C Chua; T S Howe
Journal:  J Bone Joint Surg Br       Date:  2007-03

3.  Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.

Authors:  T Mashiba; S Hui; C H Turner; S Mori; C C Johnston; D B Burr
Journal:  Calcif Tissue Int       Date:  2005-09-08       Impact factor: 4.333

4.  Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles.

Authors:  T Mashiba; C H Turner; T Hirano; M R Forwood; C C Johnston; D B Burr
Journal:  Bone       Date:  2001-05       Impact factor: 4.398

5.  Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.

Authors:  J Li; T Mashiba; D B Burr
Journal:  Calcif Tissue Int       Date:  2001-11       Impact factor: 4.333

6.  Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study.

Authors:  Roland D Chapurlat; Monique Arlot; Brigitte Burt-Pichat; Pascale Chavassieux; Jean Paul Roux; Nathalie Portero-Muzy; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2007-10       Impact factor: 6.741

7.  Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.

Authors:  L-G Ste-Marie; E Sod; T Johnson; A Chines
Journal:  Calcif Tissue Int       Date:  2004-10-14       Impact factor: 4.333

8.  An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?

Authors:  Ernest Beng Kee Kwek; Seo Kiat Goh; Joyce Suang Bee Koh; Meng Ai Png; Tet Sen Howe
Journal:  Injury       Date:  2008-01-28       Impact factor: 2.586

9.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

10.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Authors:  B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507

View more
  1 in total

1.  The effect of alendronate treatment on cortical thickness of the proximal femur in postmenopausal women.

Authors:  Maryam Mobini; Leyla Dehghan; Gholamali Yosefi; Alireza Mohammadpour; Rohollah Abdi
Journal:  Med J Islam Repub Iran       Date:  2016-02-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.